In a world where medical solutions are constantly evolving, OLIGOFASTX emerges as a beacon of hope for those battling rare diseases with no existing treatments. This groundbreaking project spearheaded by our CDMO aims to revolutionize therapy development, paving the way for novel oligonucleotide-based treatments like antimiRNAs, siRNAs, and aptamers. With OLIGOFASTX, we’re not just creating therapies – we’re shaping a future where patients have access to life-changing treatments th...

Amidst the evolving landscape of the COVID-19 pandemic, our company has embarked on an essential project named STABVAC4COV. This groundbreaking initiative aims to develop mRNA-based vaccines tailored specifically to combat the highly transmissible Delta variant of SARS-CoV-2. With the main objective of creating an effective preventive measure against the Delta variant, our dedication to innovation and public health shines brighter than ever. Join us on this critical journey towards a safer, heal...

We are thrilled to announce a groundbreaking project that has the potential to revolutionize the treatment landscape for inflammatory diseases. Thanks to the collaboration between our company and the support of CDTI and FEDER funds, we are embarking on the development of a biosimilar for Certolizumab-C1. This biosimilar, produced in the filamentous fungus Myceliophthora thermophila C1, holds promise in offering cost-effective and accessible treatment options to patients in need. With this projec...

We are thrilled to announce the launch of our latest endeavor: the construction and procurement of a state-of-the-art GMP certified facility for cell bank generation services. Supported by the European Regional Development Fund (ERDF) of the European Union and the Junta de Castilla y León, through the Instituto para la Competitividad Empresarial de Castilla y León (ICE), this project signifies a monumental step forward in our mission to enhance competitiveness and innovation within the biophar...

We’re thrilled to announce our latest endeavor: the research and development of a C1-expressed biosimilar certolizumab for the treatment of inflammatory diseases. This groundbreaking project, generously funded by the ERDF of the European Union and the Junta de Castilla y León through the ICE, underscores our commitment to pushing the boundaries of biopharmaceutical innovation. With the ultimate goal of improving patient outcomes and advancing the field of biomedicine, this project represe...